Ipca Laboratories Limited (NSE: IPCALAB) reported Revenue from Operations for Q3 FY23 of ₹1,546 Crore up from ₹1,430.47 Crore year on year, a growth of 8%. The Consolidated Net Profit of ₹107.84 Crore, down 45% from ₹196.96 Crore in the same quarter of the previous year. The Earnings per Share is ₹4.25 for this quarter.
Ipca Laboratories Limited Q3 FY23; Revenue Increased To ₹1,546 Crore
Tags: pharmaceuticals
Related Post
- NLC India Ltd Q2FY25; 10% fall in Profits
NLC India is engaged in the business of mining of lignite and generation of power…
-
NHPC Ltd Q2FY25; 37% fall in Profits
NHPC, a Mini Ratna category I public sector utility, is Government of India’s flagship hydroelectric…
-
Ashok Leyland Ltd Q2FY25; 35% rise in Profits
Ashok Leyland is the flagship Company of the Hinduja group, having a long-standing presence in…